Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 10—October 2017

Antimicrobial Drug Prescription and Neisseria gonorrhoeae Susceptibility, United States, 2005–2013

Robert D. KirkcaldyComments to Author , Monina G. Bartoces, Olusegun O. Soge, Stefan Riedel, Grace Kubin, Carlos Del Rio, John Papp, Edward W. Hook, and Lauri A. Hicks
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, M.G. Bartoces, J.R. Papp, L.A. Hicks); University of Washington, Seattle, Washington, USA (O.O. Soge); Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA (S. Riedel); Texas Department of State Health Services, Austin, Texas, USA (G. Kubin); Emory University, Atlanta (C. Del Rio); University of Alabama at Birmingham, Birmingham, Alabama, USA (E.W. Hook III)

Main Article

Table 2

Adjusted linear regression coefficients for change in antimicrobial geometric mean MIC associated with 10% increase in corresponding antimicrobial prescribing rate for 23 sites, Gonococcal Isolate Surveillance Project, United States, 2005–2013*

Effect β coefficient SE d.f. 95% CI of β coefficient
  Time −0.0087 0.003 155 −0.0146, −0.0029
  Macrolide prescribing†
−0.0502, 0.0191
  Time 0.0011 0.0001 109 0.0008, 0.0014
  Cephalosporin prescribing‡
−0.0010, 0.0041
  Time 0.0004 0.0001 155 0.0002, 0.0005
  Cephalosporin prescribing‡
−0.0009, 0.0013
  Time 0.0004 0.0021 155 −0.0038, 0.0045
  Fluoroquinolone prescribing§ 0.0004 0.0230 155 −0.0451, 0.0458

*All models were adjusted for percent of MSM at each site (using GISP data), race (percentage of men coded as black versus non-black in GISP data) percentage,and geographic region. Time was based on 1-year intervals. Estimate is statistically significant if the 95% CI of β coefficient does not cross 0.
†Per 10% increase in macrolide prescribing during the previous year; includes azithromycin, clarithromycin, and erythromycin.
‡Per 10% increase in cephalosporin prescribing during the previous year; includes cefaclor, cefadroxil, cefdinir, cefditoren pivoxil, cefixime, cefpodoxime proxetil, cefprozil, ceftibuten, cefuroxime axetil, cephalexin, cephradine, and loracarbef.
§Per 10% increase in fluoroquinolone prescribing during the previous year; includes ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin.

Main Article

Page created: September 18, 2017
Page updated: September 18, 2017
Page reviewed: September 18, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.